Literature DB >> 30153764

Treatment of massive liver metastasis of breast cancer during pregnancy: first report of a complete remission with trastuzumab and review of literature.

Fatih Aktoz1, Anil Can Yalcin2, Hasan Salih Yüzdemir2, Deniz Akata3, Murat Gültekin4.   

Abstract

Background: Metastatic breast cancer diagnosis is the most common malignancy in pregnancy and the incidence of it has been increasing among the pregnant women due to advancing maternal age within the populations. However, there are limited data about the use of trastuzumab during pregnancy with conflicting results.Case history: A 37-year-old pregnant female patient was admitted to our hospital with the metastatic breast cancer diagnosis. An MRI study showed metastatic solid masses in all lobes and segments of the patient's liver. Patient was treated with weekly docetaxel and trastuzumab regimen from 22 to 34 weeks and labored electively at the 35th gestational week. Antenatal follow-up of the fetus showed all normal ranges without any complications. An abdominal MRI following the labor revealed complete clearance of liver metastasis.Conclusions: Use of trastuzumab during pregnancy is debated due to the limited number of cases reported in the literature. This article gives a summary of the existing data where the outcome was a complete remission in disease with normal fetal development during pregnancy.

Entities:  

Keywords:  Breast cancer; docetaxel; liver metastasis; pregnancy; trastuzumab

Mesh:

Substances:

Year:  2018        PMID: 30153764     DOI: 10.1080/14767058.2018.1517308

Source DB:  PubMed          Journal:  J Matern Fetal Neonatal Med        ISSN: 1476-4954


  2 in total

1.  Use of trastuzumab in treating breast cancer during pregnancy: a systematic review and meta-analysis.

Authors:  Lin-Yu Xia; Qing-Lin Hu; Qing Zhou
Journal:  BMC Womens Health       Date:  2021-04-21       Impact factor: 2.809

2.  Nanosomal docetaxel lipid suspension based chemotherapy in a pregnant MBC patient - a case report.

Authors:  Rajkumar Ramaswamy; Nisarg Joshi; Mujtaba A Khan; Seerin Siddhara
Journal:  Onco Targets Ther       Date:  2019-07-15       Impact factor: 4.147

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.